U.S. markets close in 5 hours 3 minutes

XOMA Corporation (XOMA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
35.76-0.44 (-1.22%)
As of 10:48AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Outside Bar (Bearish)

Outside Bar (Bearish)

Previous Close36.20
Open36.39
Bid35.75 x 1000
Ask36.92 x 1100
Day's Range35.76 - 36.95
52 Week Range14.14 - 46.32
Volume10,270
Avg. Volume43,883
Market Cap394.15M
Beta (5Y Monthly)0.93
PE Ratio (TTM)N/A
EPS (TTM)-1.26
Earnings DateNov 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est46.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Xoma (XOMA) to Report Q4 Results: Wall Street Expects Earnings Growth
    Zacks

    Xoma (XOMA) to Report Q4 Results: Wall Street Expects Earnings Growth

    Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • XOMA to Present at Upcoming Investor Conferences
    GlobeNewswire

    XOMA to Present at Upcoming Investor Conferences

    EMERYVILLE, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at the following upcoming investor conferences: The Cowen 41st Annual Virtual Health Care Conference. Mr. Neal will be featured in a panel session entitled, “Blazing New Paths in Clinical Development and Structure” on Tuesday, March 2, 2021 at 2:10 PM ET. The session will be available via live webcast to conference attendees.H.C. Wainwright Global Life Science s Conference. The presentation will be available on demand beginning March 9, 2021 at 7:00 AM ET and can be accessed at http://bit.ly/3k8O9yj. The presentation can also be accessed by visiting the investor relations section of the Company’s website at www.xoma.com. A replay of the presentation will be available and archived on the site for 90 days after the event. About XOMA CorporationXOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies. The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics. The Company’s royalty-aggregator business model includes acquiring additional licenses to programs with third-party funding. For more information, visit www.xoma.com. Forward-Looking Statements/Explanatory NotesCertain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the potential of XOMA’s portfolio of partnered programs and licensed technologies generating substantial milestone and royalty proceeds over time, creating additional value for the stockholders and cash sufficiency forecast. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, our third-party licensees will not be able to market them. Other potential risks to XOMA meeting these expectations are described in more detail in XOMA's most recent filing on Form 10-K and in other SEC filings. Consider such risks carefully when considering XOMA's prospects. Any forward-looking statement in this press release represents XOMA's views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law. EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments. As of the date of this press release, all assets in XOMA’s milestone and royalty portfolio are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of these assets will become commercially available. Investor contact:Juliane SnowdenOratorium Group, LLC+1 646-438-9754jsnowden@oratoriumgroup.com Media contact:Kathy VincentKV Consulting & Management+1 310-403-8951kathy@kathyvincent.com

  • XOMA to Present at H.C. Wainwright Virtual BioConnect 2021 and Biotech Showcase Digital Conferences
    GlobeNewswire

    XOMA to Present at H.C. Wainwright Virtual BioConnect 2021 and Biotech Showcase Digital Conferences

    EMERYVILLE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at two upcoming investor conferences: * H.C. Wainwright Virtual BioConnect 2021 Conference taking place January 11-14, 2021.  XOMA’s presentation will be available on demand beginning January 11, 2021 at 6:00 AM ET and can be accessed at http://bit.ly/3hFUIaA. * Biotech Showcase Digital Conference taking place January 11-15, 2021.  The Company’s presentation will be available to registered participants.The presentations can also be accessed by visiting the investor relations section of the Company’s website at www.xoma.com.  Replays of the presentations will be available and archived on the site for 90 days after the event.About XOMA Corporation XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies.  The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas.  Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics.  The Company’s royalty-aggregator business model includes acquiring additional licenses to programs with third-party funding.  For more information, visit www.xoma.com.Forward-Looking Statements/Explanatory Notes Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the potential of XOMA’s portfolio of partnered programs and licensed technologies generating substantial milestone and royalty proceeds over time, creating additional value for the stockholders and cash sufficiency forecast.  These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, our third-party licensees will not be able to market them.  Other potential risks to XOMA meeting these expectations are described in more detail in XOMA's most recent filing on Form 10-K and in other SEC filings.  Consider such risks carefully when considering XOMA's prospects.  Any forward-looking statement in this press release represents XOMA's views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date.  XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law.EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development.  Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.  References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.As of the date of this press release, all assets in XOMA’s milestone and royalty portfolio are investigational compounds.  Efficacy and safety have not been established.  There is no guarantee that any of these assets will become commercially available.Investor contact: Juliane Snowden Oratorium Group, LLC +1 646-438-9754 jsnowden@oratoriumgroup.com Media contact: Kathy Vincent KV Consulting & Management +1 310-403-8951 kathy@kathyvincent.com